Press release
Cyclin-Dependent Kinase Inhibitor Pipeline Appears Robust With 45+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Explore our latest breakthroughs in Cyclin-Dependent Kinase Inhibitor Research. Learn more about our innovative pipeline today! @ Cyclin-Dependent Kinase Inhibitor Pipeline Outlook [https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Cyclin-Dependent Kinase Inhibitor Pipeline Report
* In July 2025, Eli Lilly and Company announced a Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy.
* DelveInsight's Cyclin Dependent Kinase Inhibitor pipeline report depicts a robust space with 45+ active players working to develop 52+ pipeline therapies for Cyclin Dependent Kinase Inhibitor treatment.
* The leading Cyclin Dependent Kinase Inhibitor Companies such as G1 Therapeutics, Betta Pharmaceuticals Co Ltd, Eli Lilly and Company, Pfizer, Tiziana Life Sciences LTD, GenFleet Therapeutics, Vincerx Pharma, Syros Pharmaceuticals, BeyondBio, Kronos Bio, Qurient Co, Sumitomo Pharma, OnKure Therapeutics, Biolexis Therapeutics, InSilico Medicine, Avenzo Therapeutics and others.
* Promising Cyclin Dependent Kinase Inhibitor Therapies such as Palbociclib PD-0332991, Abemaciclib, Anastrozole, Letrozole, Vismodegib , and others.
Stay informed about the cutting-edge advancements in Cyclin-Dependent Kinase Inhibitor treatments. Download for updates and be a part of the revolution in Oncology Care @ Cyclin-Dependent Kinase Inhibitor Clinical Trials Assessment [https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Cyclin-Dependent Kinase Inhibitor Emerging Drugs Profile
* Abemaciclib: Eli Lilly and Company
Abemaciclib selectively inhibits CDK4 and CDK6 with low nanomolar potency. These enzymes are responsible for phosphorylating and thus deactivating the retinoblastoma protein, which plays a role in cell cycle progression from the G1 (first gap) to the S (synthesis) phase. Blocking this pathway prevents cells from progressing to the S phase, thereby inducing apoptosis (cell death). In vitro analysis using cancer cell lines shows that abemaciclib induces nonapoptotic cell death characterized by the formation of cytoplasmic vacuoles derived from lysosomes. The drug was approved for use in combination with endocrine therapy (such as tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. Currently, the drug is in the Phase III stage of its development for the treatment of Liposarcoma and Prostate cancer.
* GFH-009: GenFleet Therapeutics/ Sellas Life Sciences Group
GFH009 is a potent and highly selective small-molecule inhibitor of CDK9 with more than 100 times selectivity over other CDK subtypes. Preclinical data have also suggested the potential anti-tumor effects of GFH009 in combination with BCL-2 inhibitors. As a potent and highly selective small molecule CDK9 inhibitor, GFH009 exhibits strong apoptosis-inducing and anti-proliferative activities in multiple human cell lines and animal models of diseases. It effectively inhibits the growth of tumor in various xenograft models and significantly improves survival of tumor bearing animals. The drug is currently in Phase II stage of Clinical trial evaluation for the treatment Hematological malignancies.
* Enitociclib: Vincerx Pharma
Enitociclib is a potent and selective CDK9 inhibitor currently in clinical development. The small molecule inhibitor targets P-TEFb/CDK9 and has shown robust pathway modulation as well as efficacy and safety in several preclinical tumor models and in early phase clinical studies. Enitociclib was identified as a top hit in small molecule inhibitor screening and exposure to Enitociclib for 96 hours against a representative panel of MM cell lines (NCI-H929, MM.1S, OPM-2, and U266B1) demonstrated significant cytotoxic activity, with IC50 values ranging from 36 to 78 nM. Vincerx Pharma is focused on Phase I/II study with the National Institutes of Health (NIH) evaluating combination of Enitociclib and Venetoclax and prednisone (VVIP) in diffuse large B-cell lymphoma (DLBCL) and peripheral T Cell Lymphoma (PTCL).
* AVZO-021: Avenzo Therapeutics Inc.
AVZO-021, also known as ARTS-021, is a promising clinical-stage drug developed by Avenzo Therapeutics, Inc. It is a highly potent and selective inhibitor of cyclin-dependent kinase 2 (CDK2), primarily aimed at treating hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer, as well as cancers with cyclin E1 (CCNE1) amplification. Currently, the drug is in the Phase I/II stage of its development for the treatment of triple negative breast cancer.
The Cyclin-Dependent Kinase Inhibitor Pipeline Report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Cyclin-Dependent Kinase Inhibitor with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cyclin-Dependent Kinase Inhibitor Treatment.
* Cyclin-Dependent Kinase Inhibitor Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Cyclin-Dependent Kinase Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cyclin-Dependent Kinase Inhibitor market.
Learn more about Cyclin-Dependent Kinase Inhibitor Drugs opportunities in our groundbreaking Cyclin-Dependent Kinase Inhibitor research and development projects @ Cyclin-Dependent Kinase Inhibitor Unmet Needs [https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Cyclin-Dependent Kinase Inhibitor Companies
G1 Therapeutics, Betta Pharmaceuticals Co Ltd, Eli Lilly and Company, Pfizer, Tiziana Life Sciences LTD, GenFleet Therapeutics, Vincerx Pharma, Syros Pharmaceuticals, BeyondBio, Kronos Bio, Qurient Co, Sumitomo Pharma, OnKure Therapeutics, Biolexis Therapeutics, InSilico Medicine, Avenzo Therapeutics and others.
Cyclin-Dependent Kinase Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Cyclin-Dependent Kinase Inhibitor Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Discover the latest advancements in Cyclin-Dependent Kinase Inhibitor treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Cyclin-Dependent Kinase Inhibitor Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Cyclin-Dependent Kinase Inhibitor Pipeline Report
* Coverage- Global
* Cyclin-Dependent Kinase Inhibitor Companies- G1 Therapeutics, Betta Pharmaceuticals Co Ltd, Eli Lilly and Company, Pfizer, Tiziana Life Sciences LTD, GenFleet Therapeutics, Vincerx Pharma, Syros Pharmaceuticals, BeyondBio, Kronos Bio, Qurient Co, Sumitomo Pharma, OnKure Therapeutics, Biolexis Therapeutics, InSilico Medicine, Avenzo Therapeutics and others.
* Cyclin Dependent Kinase Inhibitor Therapies- Palbociclib PD-0332991, Abemaciclib, Anastrozole, Letrozole, Vismodegib , and others.
* Cyclin-Dependent Kinase Inhibitor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Cyclin-Dependent Kinase Inhibitor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Cyclin-Dependent Kinase Inhibitor Pipeline on our website @ Cyclin-Dependent Kinase Inhibitor Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Cyclin-Dependent Kinase Inhibitor : Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Cyclin-Dependent Kinase Inhibitor - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Abemaciclib: Eli Lilly and Company
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* GFH-009: GenFleet Therapeutics/ Sellas Life Sciences Group
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Product Name: Company Name
* Preclinical Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Cyclin-Dependent Kinase Inhibitor Key Companies
* Cyclin-Dependent Kinase Inhibitor Key Products
* Cyclin-Dependent Kinase Inhibitor- Unmet Needs
* Cyclin-Dependent Kinase Inhibitor- Market Drivers and Barriers
* Cyclin-Dependent Kinase Inhibitor- Future Perspectives and Conclusion
* Cyclin-Dependent Kinase Inhibitor Analyst Views
* Cyclin-Dependent Kinase Inhibitor Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cyclindependent-kinase-inhibitor-pipeline-appears-robust-with-45-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cyclin-dependent-kinase-inhibitor-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cyclin-Dependent Kinase Inhibitor Pipeline Appears Robust With 45+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4105407 • Views: …
More Releases from ABNewswire
Top 6 Deck Builders In Kansas City For Stunning Outdoor Spaces
Outdoor living has evolved to become something more.
It is now a lifestyle choice.
Today's families seek spaces that harmonize with the natural world, yet remain as comfortable and well-designed as rooms in their homes. Patios and pergolas aren't an afterthought, but an absolute must that adds significant value to your property and makes everyday life better.
In areas with seasonal weather, where people can be outside for most of the year, homeowners…
Dash Capital Expands Zero Interest Business Loans in Detroit Following Unprecede …
Dash Capital's expansion in Detroit reflects strong demand from local businesses for flexible, fast funding solutions that support growth and operational needs across the Motor City's diverse economic landscape.
The Detroit business landscape continues to show remarkable resilience and growth potential, prompting Dash Capital to expand its funding programs in response to overwhelming demand from local entrepreneurs. This expansion comes at a time when Motor City businesses are actively seeking alternative…
Jacksonville Family Business Expands Concrete Washing Services Amid Growing Prop …
Nubirth Pressure Washing, a family-owned company serving Jacksonville since 2004, reflects the growing demand for specialized exterior property cleaning in Northeast Florida, offering comprehensive surface restoration services.
Jacksonville, FL - The Northeast Florida property maintenance industry has witnessed significant growth in specialized cleaning services as homeowners and businesses prioritize exterior property care. Local family-owned company Nubirth Pressure Washing [https://www.google.com/maps/place/Nubirth+Pressure+Washing/@30.3340387,-81.7122184,17z/data=!3m1!4b1!4m6!3m5!1s0x88e5b9c01d715555:0xd2c2470a4640f2be!8m2!3d30.3340387!4d-81.7122184!16s%2Fg%2F11vk2l_v57!5m1!1e3?entry=ttu&g_ep=EgoyMDI1MDgyNS4wIKXMDSoASAFQAw%3D%3D] represents this trend, having served the Jacksonville area since 2004 with comprehensive…
A-Class Moving & Storage Expands Direct Delivery Network, Positioning Miramar Mo …
A-Class Moving & Storage, based in Miramar, has expanded its direct delivery network across South Florida, strengthening its position as a leading moving company and reliable alternative to traditional van line brokers. The growth allows the family-owned business to serve more customers while preserving its personalized service standards.
A-Class Moving & Storage has announced a significant expansion of its direct delivery network throughout South Florida, establishing the business as a leading…
More Releases for Kinase
Cancer Tyrosine Kinase Inhibitors Market Cancer Tyrosine Kinase Clinical Pipelin …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. The Journey: Genesis to Present of Tyrosine Kinase Inhibitors
2. Tyrosine Kinase: An Overview
3. Tyrosine Kinases Inhibitors: Promising Tools for Targeted Cancer Therapies
4. Types of Tyrosine Kinase Receptors
4.1 Epidermal Growth Factor Receptor
4.1.1 Types of Epidermal Growth Factor Receptor
4.1.2 Epidermal Growth Factor Receptor & Ligands
4.1.3…
Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Bet …
According to the recently published report 'Mitogen Activated Protein Kinase Kinase Kinase 7 - Pipeline Review, H1 2017'; Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.
Request Free Sample Report - http://www.marketresearchhub.com/enquiry.php?type=S&repid=1157712
Mitogen Activated Protein Kinase Kinase Kinase 7…
Tyrosine Protein Kinase JAK3 (Janus Kinase 2 or JAK3 or EC 2.7.10.2) – Pharmac …
Market Research Hub report titled ‘Tyrosine Protein Kinase JAK3 Pipeline’ (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Tyrosine-protein kinase JAK3 is an enzyme encoded by the JAK3 gene. It is involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. It plays a…
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline …
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) pipeline Target constitutes close to 29 molecules. Out of which approximately 29 molecules are developed by Companies. The latest report Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H1 2017, outlays comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics, complete with…
Orbis Research - Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Cataly …
Description:
Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) pipeline Target constitutes close to 22 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes. The latest report Cyclin Dependent Kinase 9…
Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stres …
Market Reports Centers, Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Pipeline Review, H2 2016, provides in depth analysis on Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c…
